US OptionsDetailed Quotes

FBIO241018P5000

Watchlist

0.00
0.000.00%

15min DelayTrading Oct 2 09:30 ET

0.00High0.00Low

Fortress Biotech Stock Discussion

Clintzilla

Sep 19 19:49

$Fortress Biotech (FBIO.US)$ TBIO made me look.. ;) almost time.. grab a starter if your patient instead of chasing 3-4 later on

Trytosaveabit

Jul 19 20:12

Update

$Fortress Biotech (FBIO.US)$ Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity
- SEC Filing

Trytosaveabit

May 16 04:17

Make a note

$Fortress Biotech (FBIO.US)$ Reuters· just
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024

101539447

Apr 8 20:18

$Fortress Biotech (FBIO.US)$ even after good resilt thus share is going down. holding since last 3 months now.

carlton griffiths

Mar 25 14:50

$Fortress Biotech (FBIO.US)$ 👀 🤔

Moomoo AI

Mar 7 18:29

The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.

Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Fly 29% But Investors Aren't Buying For Growth

Trytosaveabit

Mar 7 18:05

Update

$Fortress Biotech (FBIO.US)$ $Mustang Bio (MBIO.US)$ City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...

Trytosaveabit

Mar 4 21:36

News

$Fortress Biotech (FBIO.US)$ Fortress Biotech And Cyprium Therapeutics Announce $4.1M Grant From NINDS To Further ThenDevelopment Of AAV-ATP7A Gene Therapy For Menkes Disease

Joy Boy or Bringer

Jan 29 15:02

FDA Lover

March 16th, the next FDA review... zzz I turn to be very interested following these FDA news
$OptiNose (OPTN.US)$
when are the next date for $Checkpoint Therapeutics (CKPT.US)$ , $Fortress Biotech (FBIO.US)$ , and $Brainstorm Cell Therapeutics (BCLI.US)$ ?
all of these stocks currently not good fundamentally... some even minus PBV

OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis

Moomoo AI

Jan 9 18:57

Fortress Biotech's low P/S ratio may be due to anticipated poor growth or falling revenue. Its forecast growth being lower than the industry average could be causing its P/S to lag behind peers. This suggests the share price may not rise significantly soon.

The Market Doesn't Like What It Sees From Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Yet As Shares Tumble 28%

No comment yet